Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Feb;37(1):117-126.
doi: 10.1016/j.annpat.2016.12.001. Epub 2017 Jan 19.

[Immunotherapy in Brain Tumors]

[Article in French]
Affiliations
Review

[Immunotherapy in Brain Tumors]

[Article in French]
Emilie De Carli et al. Ann Pathol. .

Abstract

Diffuse gliomas represent the most common primary central nervous system (CNS) tumors in adults and children alike. Glioblastoma is the most frequent and malignant form of diffuse glioma with a median overall survival of 15 months despite aggressive treatments. New therapeutic approaches are needed to prolong survival in this always fatal disease. The CNS has been considered for a long time as an immune privileged organ, in part because of the existence of the blood-brain barrier. Nonetheless, immunotherapy is a novel approach in the therapeutic management of glioma patients, which has shown promising results in several clinical trials, especially in the adult population. Vaccination, with or without dendritic cells, blockade of the immune checkpoints, and adoptive T cell transfer are the most studied modalities of diffuse glioma immunotherapy. The future most likely resides in combinatorial approaches, with administration of conventional treatments (surgery, radiochemotherapy) and immunotherapy following yet to determine schedules.

Keywords: Adoptive T cell transfer; Blocage des points de contrôle immunitaires; Brain tumor; Diffuse glioma; Glioblastoma; Glioblastome; Gliome diffus; Immune checkpoint blockade; Immunotherapy; Immunothérapie; Transfert adoptif de lymphocytes T; Tumeur cérébrale; Tumor vaccine; Vaccin tumoral.

Similar articles

  • Cellular immunotherapy for malignant gliomas.
    Lin Y, Okada H. Lin Y, et al. Expert Opin Biol Ther. 2016 Oct;16(10):1265-75. doi: 10.1080/14712598.2016.1214266. Epub 2016 Jul 29. Expert Opin Biol Ther. 2016. PMID: 27434205 Free PMC article. Review.
  • [What's next in glioblastoma treatment: Tumor-targeted or immune-targeted therapies?].
    Schernberg A, Marabelle A, Massard C, Armand JP, Dumont S, Deutsch E, Dhermain F. Schernberg A, et al. Bull Cancer. 2016 May;103(5):484-98. doi: 10.1016/j.bulcan.2016.02.014. Epub 2016 Mar 28. Bull Cancer. 2016. PMID: 27032303 Review. French.
  • Immunothérapie des glioblastomes.
    Baldini C, Romano PM, Varga A, Champiat S, Dumont S, Dhermain F, Louvel G, Marabelle A, Postel-Vinay S, Angevin E, Gazzah A, Ribrag V, Bahleda R, Michot JM, Hollebecque A, Soria JC, Massard C. Baldini C, et al. Bull Cancer. 2018 Dec;105 Suppl 1:S59-S67. doi: 10.1016/S0007-4551(18)30391-6. Bull Cancer. 2018. PMID: 30595200 Review. French.
  • Advances in Immunotherapy for Glioblastoma Multiforme.
    Huang B, Zhang H, Gu L, Ye B, Jian Z, Stary C, Xiong X. Huang B, et al. J Immunol Res. 2017;2017:3597613. doi: 10.1155/2017/3597613. Epub 2017 Feb 19. J Immunol Res. 2017. PMID: 28299344 Free PMC article. Review.
  • Emerging immunotherapies for glioblastoma.
    Desai R, Suryadevara CM, Batich KA, Farber SH, Sanchez-Perez L, Sampson JH. Desai R, et al. Expert Opin Emerg Drugs. 2016 Jun;21(2):133-45. doi: 10.1080/14728214.2016.1186643. Expert Opin Emerg Drugs. 2016. PMID: 27223671 Free PMC article. Review.
See all similar articles

MeSH terms

LinkOut - more resources

Feedback